All treatments
Treatment
Xospata 40 mg film-coated tablets clinical trials
2 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
An open-label, phase 2 study, evaluating the efficacy of treatment with Gilteritinib in measurable residual disease eradication in patients with FLT3-ITD mutated acute myeloid leukemia
This study is looking at a new way to treat a type of blood cancer called acute myeloid leukaemia (AML) with a specific gene change (FLT3-ITD). We want to see if the medicine, Xospata, can completely clear tiny traces of cancer cells in the body.
For: Acute myeloid leukaemia · Acute myeloid leukaemiaGreece - AuthorisedTherapeutic exploratory (Phase II)
A Phase II, Open-Label, multicentre, study investigating tolerability and efficacy of Gilteritinib in combination with fludarabine, cytarabine and idarubicin (FLAI) as induction therapy of newly diagnosed non-M3 FLT3-positive acute myeloid leukemia.GIMEMA AML2924
This study looks at a new drug, Xospata, combined with standard chemotherapy for adults with a type of acute myeloid leukaemia (AML) that has a specific genetic marker called FLT3. We want to see how well this new combination works and if it's safe for patients who have just been diagnosed.
For: newly diagnosed non-M3 FLT3-positive acute myeloid leukemiaItaly